In addition, it is approved for locally advanced or metastatic HER2-low (IHC 1+ or IHC 2+/FISH‐) BC patients who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.